JDRF award supports study of potential target for blocking type ... (enase may contribute to the development ...)

JDRF award supports study of potential target for blocking type 1 diabetes

Date:9/2/2009

enase may contribute to the development of diabetes and opens the possibility of directly targeting this enzyme for treatment," Dr. Holman said. "Based on this important discovery, Dr. Nadler has already begun testing our lipoxygenase inhibitors in the hopes of generating new treatments for diabetes. His preliminary results are very promising and with his recent funding by the JDRF, we hope to make further progress."

"JDRF is thrilled to be supporting Dr. Nadler's work at EVMS as this research may represent an important step toward the development of a new therapeutic strategy for treating type 1 diabetes," said Patricia Kilian, PhD, director of regeneration at JDRF.

Often diagnosed in children and young adults, Type 1 diabetes, previously known as juvenile diabetes, is an autoimmune disorder associated with the destruction of insulin-producing beta cells. Without insulin, the body is unable to process sugars and starches leaving it unable to convert them into energy for movement, growth, repair and other functions.

'/>"/>

Contact: Jina Gaines
gainesjn@evms.edu
757-446-6074
Eastern Virginia Medical School
Source:Eurekalert

0

GOOD

Page: 1 2
Related medicine news :

1. ING Awards $100,000 in Grants to Combat Childhood Obesity
2. Empire Blue Cross Blue Shield Awarded NCQAs Accreditation Status of Excellent
3. Regence Foundation Awards Nearly $250,000 in Grants to Northwest Nonprofits
4. Vigilan Earns Honor in the 2009 Product & Technology Awards Program by Mature Market Resource Center
5. American Chemical Society Awards John R. Engen for Scientific Achievements
6. Frost & Sullivan Recognizes Carestream Health with the 2009 Latin American Computed Radiology Customer Value Leadership Award
7. Nielsen Announces Final Entry Deadline Extension of September 10th for the First-Ever CLIO Healthcare Awards
8. Rhode Island Hospital awarded $11 million, 5-year renewal
9. Lundbeck Inc. Recognized With Award of Excellence in Corporate Achievement for Its Commitment to Huntingtons Disease Community
10. Sundia Receives the Highest Growth Potential Award from Zhangjiang
11. The Eye Institute Receives 2009 Best of Rock Springs Award from U.S. Commerce Association

Post Your Comments:

(Date:11/20/2009)...ire-USNewswire/ -- The American Dental Association...ration (FDA) to establish appropriate classificati...oncern about the safety of whitening products that...fessional consultation or examination by a dentist...mically based tooth whitening or bleaching agents ...

(Date:11/20/2009)...wire-USNewswire/ -- The following is a statement b...Health Care Association: ,, "The Nevada Health ... Majority Leader Harry Reid for his leadership in ... protecting every Nevada seniors, ongoing access t...rength and viability of our state,s vital frontlin...

(Date:11/20/2009)...ildren with chronic kidney disease often fail to d...sits increasing a child,s risk for serious heart ... Children,s Center and other institutions. A repor... American Society of Nephrology. , Researchers...ing regular doctor visits to readings obtained via...

(Date:11/20/2009)...g 90-day supply, study finds , , FRIDAY,...supply of prescription drugs is up to one-third ch... a new study. , U.S. researchers analyzed 26,85...and 2005, and found that patients who bought a thr...d an average 29 percent in out-of-pocket costs. Af...

(Date:11/20/2009)...es increased food insecurity as many face problem ...swire/ -- Project Bread, the state,s leading anti-...oming annual status report on hunger in the Common...eport, caused by high unemployment, point to 554,0...er. Food insecurity has found its way into middle ...

Breaking Medicine News(10 mins):Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2 Health News:High blood pressure easy to miss in children with kidney disease 2 Health News:Three-Month Supply Lowers Drug Costs 2 Health News:554,000 in Massachusetts Struggle to Put Food on the Table 2 Health News:554,000 in Massachusetts Struggle to Put Food on the Table 3 Health News:554,000 in Massachusetts Struggle to Put Food on the Table 4

[0] American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products [0] Nevada Health Care Association (NHCA) Supports Majority Leader Reid [0] High blood pressure easy to miss in children with kidney disease [0] Three-Month Supply Lowers Drug Costs [0] 554,000 in Massachusetts Struggle to Put Food on the Table

..., Nov. 1 Arete Therapeutics Inc. today,announced ... lead compound,AR9281, for the treatment of hypert...e inhibitor of soluble epoxide hydrolase (s-EH), a...armacokinetics and pharmacodynamics for single asc...

... Nov. 1 Amedica Corporation, an,orthopedic implan...nologies, announced today that Ashok Khandkar, Ph....ice President Finance and Chief Financial,Officer,... Hotel in New York City. Mr. Khandkar and Mr. Gal...

...gland and PHILADELPHIA, November 1, Shire plc (LSE...ty biopharmaceutical company announces results for...ghts - Product sales up 41% to $543.1 million; -...ed to be at least 30% (Q2 guidance: at,least 25%)....

...nfirm environmental toxins play role in autism, as..., Nov. 1 The National Autism,Association (NAA) an...school districts to implement the "Greening Your S...nate the serious,dangers posed to children from da...

...wth Over Same Quarter Last Year - - 20%... - FY08 Revenue Projection Raised - ...ed - - Conference Call to be Held at 10:00 a.m....cal 2008 ended September 30, 2007, up 73% from $1....

...Calif., Nov. 1 The Maverick Saloon will,host a tr...ber 8, 2007 from,4 PM until 7 PM to raise research... that claimed the life of the much loved and respe...yvjoneshouse.com . The proceeds from the show wil...

Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent Amedica to Present at CIBC World Markets 18th Annual Healthcare Conference Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National 'Greening Your School' Initiative Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter Friends of Warren Zevon To Play at Maverick Saloon - Raising Awareness of Asbestos Cancer, Mesothelioma

(Date:11/20/2009)...ov. 20 Soligenix, Inc. (...y), formerly known as DOR BioPharma, Inc., a late-...it has formed a consortium to develop thermostable... acting vaccines. Soligenix received a $9.4 millio... Infectious Diseases (NIAID), a division of the Na...

(Date:11/19/2009)...ov. 19 In a series of ne..., Heska Corporation (Nasdaq: HSKA ) ("Heska" or t...w and improved website. The upgraded site is the ...rogramming to align the site with the company,s ne...go: http://www.newscom.com/cgi-bin/prnh/20000622...

(Date:11/19/2009)...Nov. 19 The D e al m...its Most Admired Corporate Dealmakers for the seco... its Most Admired Dealmaker in pharma/biotech for ...nd divestitures since January 2006. ,, Over the...tfolio with a focus on high-growth, innovation-dri...

Breaking Medicine Technology:Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2 Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3 Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4 Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5 Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6 Heska Announces Launch of New Website 2 Heska Announces Launch of New Website 3 The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2 The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3 Response Times Vary for In Hospital Heart Attacks 53388 1 Response Times Vary for In Hospital Heart Attacks 53388 2 Blood Transfusions Not Linked to Long Term Problems 53386 1 JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 1 JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 2 JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 3 JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 4

[0] Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines [0] Heska Announces Launch of New Website [0] The Deal Names Abbott Top Dealmaker for Second Consecutive Year

... 10:00 a.m. today, Thursday, August 16, 2007, MAL... (Nasdaq: AUXL ) today announced that the Company...g Administration ("FDA") to,resume its phase III c...e,for injection), formerly referred to as AA4500, ...ompany will hold a conference call today,August 16...

...plemental New Drug Application in the Fourth ...ug. 16 Cephalon, Inc. (Nasdaq:,CEPH) today announ...cal,trial of FENTORA(R) (fentanyl buccal tablet) [...d with a broad range of chronic non-cancer pain,co...nce on the primary,endpoint. Results across the 12...

Other Medicine Technology:Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 2 Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 3 Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 4 Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 5 Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 6 Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2 Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3 Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4 Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5

Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain

...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...

Medicine Products:

Quetiapine Quantitative Plasma & Urinary Amino Acids QuantiFERON-TB Gold (Local Clients Only)Qualitative Tissue Culture

JDRF award supports study of potential target for blocking type ...(enase may contribute to the development ...),Health